•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
Cathie Wood’s Ark Innovation ETF (ARKK) is heavily weighted toward innovative growth bets, and investors often closely track the fund’s most recent stock purchases and sales. Among the latest additions, Ark bought shares of Figma, CRISPR Therapeutics, and CoreWeave—three companies that the fund appears to view as high-upside opportunities despite varying levels of risk.
Figma (FIG) is the most recent stock purchased for Ark Innovation ETF, with Ark buying shares on Feb. 23. The purchase marked the third time Ark bought Figma shares during the month.
Figma ranks as the fund’s 38th-largest holding, representing about 0.66% of the portfolio. The article notes that Figma was one of a small number of stocks where Ark increased exposure in the second half of February.
Over the past six months, Figma’s stock has traded with volatility as investors weigh concerns about decelerating growth and long-term profitability. Still, the company reported sales growth of 40% year over year in the fourth quarter and an adjusted operating margin of 14% for the period.
Ark Innovation ETF also increased its position in CRISPR Therapeutics (CRSP) on Feb. 20. The article describes CRISPR as a long-standing holding for the fund and notes that the Feb. 20 purchase added more shares.
CRISPR is the second-largest holding in the ETF, accounting for 6.64% of total portfolio weight. The article characterizes CRISPR as generating relatively little revenue, citing sales of $3.5 million last year.
Despite the current revenue base, the fund’s thesis appears to depend on the potential for gene-editing drug candidates in its pipeline to reach meaningful commercialization. The article frames CRISPR as a speculative growth play that could influence the ETF’s performance over the next five years.
CoreWeave (CRWV) is a provider of data center services and has benefited from rising demand tied to AI processing. Ark purchased additional shares of CoreWeave on Feb. 20, and the article states that CoreWeave is now the 18th-largest holding in the ETF, representing roughly 2% of total holdings.
The article highlights that CoreWeave has been posting strong sales growth alongside high AI processing needs. It also points to potential catalysts for 2026, including access to large orders of Nvidia’s next-generation Rubin GPUs and Vera CPUs. The article suggests these developments could help CoreWeave attract service demand in a hardware-constrained environment.
Across the three purchases, the article emphasizes Ark Innovation ETF’s preference for innovation-driven growth opportunities. Figma and CoreWeave are positioned around scaling business momentum—software adoption and AI infrastructure demand—while CRISPR is framed as a higher-risk bet dependent on future commercialization outcomes from its pipeline.
Premium gym chains are entering a “golden era” that is ending or already in decline, as rising operating costs collide with shifting consumer preferences toward more flexible, community-based ways to exercise. Long-term memberships are shrinking, margins are pressured by higher rents and facility expenses, and competition from smaller, more personalized…
